[HTML][HTML] Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions
S Barr, S Thomson, E Buck, S Russo, F Petti… - Clinical & experimental …, 2008 - Springer
Over 90% of all cancers are carcinomas, malignancies derived from cells of epithelial origin.
As carcinomas progress, these tumors may lose epithelial morphology and acquire …
As carcinomas progress, these tumors may lose epithelial morphology and acquire …
Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
SR Dillon, C Sprecher, A Hammond, J Bilsborough… - Nature …, 2004 - nature.com
T cell–derived cytokines are important in the development of an effective immune response,
but when dysregulated they can promote disease. Here we identify a four-helix bundle …
but when dysregulated they can promote disease. Here we identify a four-helix bundle …
Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor
MJ Mulvihill, A Cooke, M Rosenfeld-Franklin… - Future medicinal …, 2009 - Future Science
Background: The IGF-1 receptor (IGF-1R) has been implicated in the promotion of
tumorigenesis, metastasis and resistance to cancer therapies. Therefore, this receptor has …
tumorigenesis, metastasis and resistance to cancer therapies. Therefore, this receptor has …
[HTML][HTML] Immuno-oncology trends: preclinical models, biomarkers, and clinical development
MR Franklin, S Platero, KS Saini… - … for ImmunoTherapy of …, 2022 - ncbi.nlm.nih.gov
The landscape in immuno-oncology (IO) has undergone profound changes since its early
beginnings up through the rapid advances happening today. The current drug development …
beginnings up through the rapid advances happening today. The current drug development …
Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer
E Buck, PC Gokhale, S Koujak, E Brown… - Molecular cancer …, 2010 - AACR
Insulin-like growth factor-1 receptor (IGF-1R) is a receptor tyrosine kinase (RTK) and critical
activator of the phosphatidylinositol 3-kinase–AKT pathway. IGF-1R is required for …
activator of the phosphatidylinositol 3-kinase–AKT pathway. IGF-1R is required for …
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors
E Buck, A Eyzaguirre, M Rosenfeld-Franklin… - Cancer research, 2008 - AACR
Epidermal growth factor receptor (EGFR) and insulin-like growth factor-I receptor (IGF-IR)
can cooperate to regulate tumor growth and survival, and synergistic growth inhibition has …
can cooperate to regulate tumor growth and survival, and synergistic growth inhibition has …
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor …
Q Ji, MJ Mulvihill, M Rosenfeld-Franklin, A Cooke… - Molecular cancer …, 2007 - AACR
Insulin-like growth factor-I receptor (IGF-IR) and its ligands, IGF-I and IGF-II, are up-regulated
in a variety of human cancers. In tumors, such as colorectal, non–small cell lung, ovarian …
in a variety of human cancers. In tumors, such as colorectal, non–small cell lung, ovarian …
TGFβ1‐induced suppression of glutathione antioxidant defenses in hepatocytes: caspase‐dependent posttranslational and caspase‐independent transcriptional …
CC Franklin, ME Rosenfeld-Franklin, C White… - The FASEB …, 2003 - Wiley Online Library
ABSTRACT TGFβ1‐induced hepatocyte apoptosis involves the production of reactive
oxygen species. An effective cellular defense mechanism against oxidative stress is the …
oxygen species. An effective cellular defense mechanism against oxidative stress is the …
Inducible expression of TGFβ, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model
GM Argast, JS Krueger, S Thomson… - Clinical & experimental …, 2011 - Springer
The progression of cancer from non-metastatic to metastatic is the critical transition in the
course of the disease. The epithelial to mesenchymal transition (EMT) is a mechanism by …
course of the disease. The epithelial to mesenchymal transition (EMT) is a mechanism by …
Preclinical use of focal radiation and immune checkpoint blockade to improve therapeutic response in an immunologically cold tumor
MR Franklin, D Draper, S Urs, S Wise - Cancer Research, 2019 - AACR
Radiotherapy is a highly utilized clinical treatment modality. More than 50% of all cancer
patients receive some type of radiation therapy during the course of their illness. In mouse …
patients receive some type of radiation therapy during the course of their illness. In mouse …